Healthy Chinese Volunteers Clinical Trial
Official title:
A Multiple-Dose, Safety and TolerabilityćPK/PD Study of Tecarfarin in Healthy Chinese Volunteers
The subjects will be admitted to the Phase I Clinical Research Center on day -1. Subjects received once-daily doses of Tecarfarin for up to 14 days.Subjects can leave the Phase I Clinical Research Center on the day 21.And returned to the research center for follow-up on the day 28 and 35.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03610880 -
To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT01720212 -
Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT03971916 -
A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT04495322 -
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.
|
Phase 1 | |
| Completed |
NCT03610867 -
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349
|
Phase 1 |